Comparison
1p35 2 Microdeletion Syndrome vs 15q Overgrowth Syndrome
Clinical comparison between 1p35 2 Microdeletion Syndrome and 15q Overgrowth Syndrome for differential diagnosis and treatment planning.
6 comparison axes
Onset
1p35 2 Microdeletion Syndrome
0-null
15q Overgrowth Syndrome
0-0
Onset patterns differ
Severity
1p35 2 Microdeletion Syndrome
severe
15q Overgrowth Syndrome
moderate
Different severity levels
Chronic
1p35 2 Microdeletion Syndrome
Chronic
15q Overgrowth Syndrome
Chronic
Differing course
Communicable
1p35 2 Microdeletion Syndrome
No
15q Overgrowth Syndrome
No
Different transmission
Body System
1p35 2 Microdeletion Syndrome
congenital
15q Overgrowth Syndrome
congenital
Same/different system
Category
1p35 2 Microdeletion Syndrome
rare-disease
15q Overgrowth Syndrome
genetic
Different category
Bottom line
1p35-2-microdeletion-syndrome-C5679992 and 15q-overgrowth-syndrome-C4749920 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 1p35 2 Microdeletion Syndrome | 15q Overgrowth Syndrome | Discriminating power |
|---|---|---|---|
| Growth pattern | No consistent growth pattern is established from the supplied data. | The name suggests overgrowth, but extent and timing are not established here. | Moderate |
| Developmental concerns | Possible developmental impact is not defined by the available evidence. | Developmental effects may occur, but a definitive profile is not established. | Low |
| Congenital presentation | Classified as congenital and severe, with onset incompletely specified. | Classified as congenital and moderate, with onset recorded as present from birth. | Moderate |
When to favor each condition
Choose 1p35 2 Microdeletion Syndrome when
A chromosomal microarray suggests a 1p35.2 deletion
The named locus matches the left condition better than a 15q finding.
High
Severe congenital phenotype without documented overgrowth
Supplied severity is severe, but this does not prove the diagnosis alone.
Low
Genetic report prioritizes a rare microdeletion
The left category is rare disease and the mechanism is deletion rather than overgrowth-associated change.
Moderate
Choose 15q Overgrowth Syndrome when
Testing identifies a relevant 15q copy-number change
The chromosomal region aligns with the right condition.
High
Clinically suspected congenital overgrowth syndrome
The syndrome name supports this consideration, pending genetic confirmation.
Moderate
Moderate rather than severe congenital course is documented
This matches the supplied severity axis but is not diagnostic by itself.
Low
How key tests differ
| Test | 1p35 2 Microdeletion Syndrome | 15q Overgrowth Syndrome | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May show a microdeletion involving 1p35.2. | May show a 15q copy-number change associated with overgrowth. | The locus and copy-number direction are central; results need laboratory and clinical correlation. |
| Karyotype | Often normal if the deletion is below karyotype resolution. | May be normal or abnormal depending on the size of the 15q change. | A normal karyotype does not exclude either condition. |
| Growth assessment | No specific growth cutoff is established here. | Overgrowth may be assessed clinically, without a universal cutoff supplied. | Measurements support evaluation but do not replace genetic confirmation. |
Prognosis comparison
1p35 2 Microdeletion Syndrome
- Outcome
- Long-term outcome is not established; supplied severity is severe.
- Factors
- Deletion size, involved genes, and individual findings may matter.
15q Overgrowth Syndrome
- Outcome
- Long-term outcome is not established; supplied severity is moderate.
- Factors
- 15q change, growth pattern, and developmental findings may matter.
Time frame: Both are described as chronic congenital conditions; no reliable timeline is supplied.
Prognosis requires individualized genetic and clinical assessment.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental disability | Risk is not quantified in the supplied data. Risk is not quantified in the supplied data. Both may warrant developmental surveillance; no definitive complication rate is established. |
| Growth-related complications | No specific growth complication is established. Overgrowth-related issues are plausible but not specified here. Avoid assuming organ effects without individual clinical evidence. |
| Medical complexity | Supplied severity is severe. Supplied severity is moderate. Severity labels do not predict individual complications or mortality. |
Patient education highlights
- HighGenetic confirmation
Diagnosis depends on validated genetic testing and clinician review, not the syndrome name alone.
- HighIndividual variability
Features and severity can vary, and many details are not established from these sparse data.
- MediumFamily implications
Inheritance and recurrence risk should be discussed with a genetics professional.